DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Phase 2

Active, not recruiting

Conditions: Carcinoid Tumors

Interventions: Drug: Ramucirumab
Drug: Somatostatin Analog

First Posted Date: 2016-06-10

Last Posted Date: 2024-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT02795858

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Phase 1

Active, not recruiting

Conditions: Recurrent Chronic Lymphoid Leukemia

Interventions: Drug: ACY-1215
Drug: Ibrutinib
Drug: Idelalisib

First Posted Date: 2016-06-01

Last Posted Date: 2024-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT02787369

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Phase 2

Terminated

Conditions: Epidermal Growth Factor Receptor
Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2016-05-12

Last Posted Date: 2019-11-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT02770014

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Drug: Tamoxifen
Drug: Endocrine Therapy
Drug: Palbociclib

First Posted Date: 2016-05-06

Last Posted Date: 2024-03-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 195

Registration Number: NCT02764541

Locations: 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Dana-Farber at St. Elizabeth's Medical Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 8 locations

CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors

Not Applicable

Completed

Conditions: Insomnia

Interventions: Behavioral: CBTI-CS via Telehealth
Behavioral: CBTI-CS
Behavioral: Sleep Hygiene

First Posted Date: 2016-04-29

Last Posted Date: 2018-12-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 56

Registration Number: NCT02756390

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy

Not Applicable

Withdrawn

Conditions: Breast Cancer

Interventions: Procedure: Axillary Lymph Node Sampling Clip

First Posted Date: 2016-04-26

Last Posted Date: 2017-11-21

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02752009

Hereditary Risk Factors for Thyroid Cancer

Not Applicable

Recruiting

Conditions: Thyroid Cancer

Interventions: Genetic: •Referral to Genetic Counselor, if indicated

First Posted Date: 2016-04-22

Last Posted Date: 2024-04-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 250

Registration Number: NCT02747888

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Advanced Non-Clear Cell Kidney Cancer

Interventions: Drug: Bevacizumab
Drug: Atezolizumab

First Posted Date: 2016-03-31

Last Posted Date: 2024-12-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 65

Registration Number: NCT02724878

Locations: 🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Phase 2

Completed

Conditions: Venous Thormboembolism

Interventions: Drug: Enoxaparin

First Posted Date: 2016-03-11

Last Posted Date: 2021-07-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT02706249

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

Phase 2

Completed

Conditions: Early Stage Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Neulasta

First Posted Date: 2016-03-04

Last Posted Date: 2022-05-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 127

Registration Number: NCT02698891

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire, United States
🇺🇸
Dana-Farber at Milford Regional Cancer Center, Milford, Massachusetts, United States

and more 1 locations

Home Terms & Conditions Privacy Policy